Amphastar Pharmaceuticals trades at a deep discount—6.7x trailing earnings—reflecting structural growth and margin challenges. Branded product growth (BAQSIMI, Primatene MIST) has not offset ...

Revenue from Vaxini was pressured by lower average selling prices linked to higher rebates and 340B discounts; these pricing headwinds are expected to persist in the near term according to management ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. Aldi shoppers across the U.S. can expect gradual changes to many ...

Image source: The Motley Fool. Amphastar Pharmaceuticals (NASDAQ:AMPH) delivered quarterly revenue growth from new launches and stable core products while facing substantial pricing and competitive ...

Changes in net revenues as compared to the first quarter of the prior year were primarily driven by: BAQSIMI ® sales decreased primarily due to a lower average selling price, as a result of a change ...

Greetings, and welcome to the Amphastar Pharmaceuticals First Quarter Earnings Call. [Operator Instructions] Please note that certain statements made during this call regarding matters that are not ...

Amphastar Pharmaceuticals (NASDAQ:AMPH) presented its corporate overview in May 2026, showcasing an ambitious strategic transformation toward proprietary and biosimilar products even as the company ...

People using a blue inhaler to help treat their asthma are being urged to contact their GP. The call comes after changes in guidelines following research which showed long-term use of the medication ...

Experts are urging anyone who is using a blue salbutamol inhaler to contact their GP. The familiar blue reliever treatment has been used by millions of asthma patients for over five decades. However ...